Tools and Strategies Driving Cancer Immunotherapy

The Scientist brings together a panel of experts who will delve into the hope and hype in an effort to educate the audience about the new findings in cancer immunotherapy.

By | February 20, 2014

The Scientist brings together a panel of experts who will delve into the hope and hype in an effort to educate the audience about the new findings in cancer immunotherapy.

A number of labs in the pharma/biotech industry and in academia are now focusing their efforts on new ways to modulate the immune system to target cancer. Advances, both in understanding immune pathways and in developing tools to target and exploit these pathways, have led to remarkable progress in this relatively new field. The Scientist brings together a panel of experts who will delve into the hope and hype in an effort to educate the audience about the new findings in cancer immunotherapy. Attendees can interact with the experts during the live webinar by asking questions and sharing their experiences on this topic.

Topics to be covered:

  • Basic concepts underlying immunomodulation for oncology
  • New drug entities: immunomodulatory agents, vaccines, monoclonal antibodies, and more
  • Challenges in drug development
  • New tools for screening and validation
  • Use of biomarkers for targeted therapies

Meet the Speakers:

Dr. Jedd Wolchok
Chief, Melanoma & Immunotherapeutics Service
Memorial Sloan-Kettering Cancer Center

 

 

Dr. Tibor Keler
Senior Vice President and Chief Scientific Officer
Celldex Therapeutics

RocklandLonza

Add a Comment

Avatar of: You

You

Processing...
Processing...

Sign In with your LabX Media Group Passport to leave a comment

Not a member? Register Now!

LabX Media Group Passport Logo

Popular Now

  1. Monsanto Buys Rights to CRISPR
    The Nutshell Monsanto Buys Rights to CRISPR

    The US agribusiness secures a global, nonexclusive licensing agreement from the Broad Institute to use the gene-editing technology for agricultural applications.

  2. How Plants Evolved Different Ways to Make Caffeine
  3. Thomson Reuters Predicts Nobelists
    The Nutshell Thomson Reuters Predicts Nobelists

    According to citation statistics, researchers behind programmed cell death pathways and CRISPR/Cas9 are among those in line for Nobel Prizes this year.

  4. ESP on Trial
    Foundations ESP on Trial

    In the 1930s, parapsychologist Joseph Banks Rhine aimed to use scientific methods to confirm the existence of extrasensory perception, but faced criticisms of dubious analyses and irreproducible results.

RayBiotech